CI

At a glance

ClinicalIndex Comparison Record
Phase 2Completed· 37 enrolled
Drug / intervention
Nesiritide +1 moredrug
Likely dose
Nesiritide 0.01MCG/KGfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT01440881
NCT01440881Phase 2Completed
CompareCT.gov

Does Nesiritide Provide Renal Protection By Attenuating the Inflammatory Response

University of Florida·interventional·Posted Sep 27, 2011·Updated Jun 6, 2014

In Brief

A Phase 2 clinical trial evaluating Nesiritide and Placebo for Renal Failure. Completed, enrolled 37 participants across 1 site.

Detailed Summary

This project evaluates whether nesiritide, human recombinant brain natriuretic peptide, confers renal protection during cardiovascular surgery by attenuating the inflammatory response.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsRenal Failure
CountriesUnited States
Collaborators--

Timeline

Phase 2CompletedFinished
20102011201220132014201520162017201820192020202120222023202420252026
First PostedSep 27, 2011
Enrollment StartApr 1, 2010
Primary CompletionDec 1, 2012
TodayJul 2, 2026
Enrollment to primary: 2.7 yearsPosted 14.8 years ago

Interventions

Nesiritidedrug

infuses at 0.01MCG/KG/min for 48 hours

Placebodrug

infuses at 0.01MCG/KG/min for 48 hours